Market Cap: $131.82M
TI
TuHURA Biosciences, Inc.
HURA
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $131.82M
TuHURA Biosciences, Inc. (Ticker: HURA), an emerging immuno-oncology company based in Tampa, Florida, is making strides in developing novel therapies aimed at overcoming the challenges of resistance t…
TuHURA Biosciences, Inc. recently fortifies its leadership team with the appointment of Amanda Garofalo, MSHS, as the new Senior Vice President of Clinical Operations. This decision comes as the immun…
TuHURA Biosciences Strengthens Leadership with Key Appointment in Oncology Development TuHURA Biosciences, Inc. is making significant strides in its pursuit of innovative cancer therapies as it announ…
TuHURA Biosciences Strengthens Leadership with Dr. Tendler's Expanded Role TuHURA Biosciences, a company specializing in immuno-oncology therapies, announces a significant leadership shift as Dr. Crai…
TuHURA Biosciences Advances Cancer Treatment with Innovative Immunotherapies TuHURA Biosciences, Inc. is making significant strides in the field of immuno-oncology, as it seeks to address one of the m…
TuHURA Biosciences Advances Cancer Therapy Development Amid Milestone Achievement TuHURA Biosciences, Inc., a Phase 3 immuno-oncology firm, marks a significant achievement in its mission to combat can…
TuHURA Biosciences Advances Cancer Treatment through Innovative Therapies TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, takes a significant step forward in cancer treatment development…
TuHURA Biosciences Advances Cancer Immunotherapy Initiatives TuHURA Biosciences, Inc. is making significant strides in the field of immune-oncology, particularly with its lead development program, a P…
TuHURA Biosciences Positions for Growth in Immuno-Oncology TuHURA Biosciences, Inc. is making significant strides in the competitive field of immuno-oncology, particularly with its lead program, IFx-2…
Breakthrough in Cancer Immunotherapy: TuHURA Biosciences Targets Delta Opioid Receptor TuHURA Biosciences, Inc. is making significant progress in the field of cancer immunotherapy with its recent disc…
TuHURA Biosciences Unveils Promising Target in Cancer Immunotherapy TuHURA Biosciences, Inc., a Phase 3 immune-oncology company, makes a groundbreaking discovery that could reshape the landscape of ca…
Skin Pharm Expands Its Reach with New Chicago Clinic Skin Pharm, a Nashville-based beauty brand known for its aesthetic skin care clinics and medical-grade products, announces the opening of its fourt…
Skin Pharm Expands Aesthetic Services with New Tampa Clinic Skin Pharm, a modern beauty brand focused on aesthetic skin care and medical-grade products, is making a significant advancement in its nati…
Innovative Approach to Aesthetic Treatments: AMI Pharm's AYP-101 Enters Phase 3 Trials AMI Pharm, a pioneering biotechnology company in the aesthetics sector, advances its lead drug candidate, AYP-101…
Innovative Advances in Aesthetic Medicine: AYP-101's Phase 3 Trial Launches AMI Pharm, a pioneering biotechnology company focused on aesthetic solutions, commences a pivotal Phase 3 clinical trial for…
Innovative Approach to Aesthetic Medicine: AMI Pharm's AYP-101 Clinical Trial AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, initiates a pivotal Phase 3 clinical…